Pipeline Overview

We are focused on the development and commercialization of innovative therapeutics for the treatment of cancer.

PreclinicalClinicalMarketed
 IndicationProof of PrincipleSafetyDose OptimizationClinical ActivityPivotalCommercial
Heme Malignancies
Emavusertib*
IRAK4
 IRAK4-driven Leukemia
(AML/MDS)

TakeAim Leukemia1

Emavusertib*
IRAK4
 IRAK4-driven Lymphoma
(NHL, CLL, WM)

TakeAim Lymphoma

Fimepinostat
HDAC/PI3K
 MYC-altered Cancers

Immune Checkpoint Inhibitors
CI-8993**
VISTA
 VISTA-expressing Cancers

CA-327*
TIM3/PDL1
 PDL1/TIM3-expressing Cancers

CA-170*
VISTA/PDL1
 PDL1/VISTA-expressing Cancers

Approved Drug
Erivedge***
Hedgehog
 Basal Cell Carcinoma

DrugIndicationStage
Heme Malignancies
Emavusertib*
IRAK4
 IRAK4-driven Leukemia
(AML/MDS)		Clinical Activity
Emavusertib*
IRAK4
 IRAK4-driven Lymphoma
(NHL, CLL, WM)		Clinical Activity
Fimepinostat
HDAC/PI3K
 MYC-altered CancersClinical Activity
Immune Checkpoint Inhibitors
CI-8993**
VISTA
 VISTA-expressing CancersSafety
CA-327*
TIM3/PDL1
 PDL1/TIM3-expressing CancersProof of Principle
CA-170*
VISTA/PDL1
 PDL1/VISTA-expressing CancersClinical Activity
Approved Drug
Erivedge***
Hedgehog
 Basal Cell CarcinomaCommercial

* IP licensed from Aurigene
** Exclusive option to license IP from ImmuNext
*** IP licensed to Genentech (Curis receives royalty income)

1) In April 2022, the U.S. Food and Drug Administration (“FDA”) placed the TakeAim Leukemia study on partial clinical hold. In August 2022, the FDA notified Curis that it may resume enrollment in the monotherapy dose finding phase of the study. The partial hold remains in place for the combination therapy and expansion phases of the study.